Biotech Hunter
Biotech Hunter
Home
Companies
Trials
People
Search
Home
/
Trials
/
NCT01181089
NCT01181089
View on ClinicalTrials.gov
Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)
PHASE1/PHASE2
Withdrawn
INTERVENTIONAL
0
Timeline
Start Date
September 30, 2010
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
BIOLOGICAL
Placebo
BIOLOGICAL
Baminercept
Sponsors
Lead Sponsor
Biogen
All Listed Sponsors
lead
Biogen
INDUSTRY